Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 1, 2016, Pages 17-22

  Perales, Miguel Angel ^a,b   Sauter, Craig S ^a,b   Armand, Philippe ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adoptive cell therapy; Autologous stem cell transplantation; Checkpoint inhibitors; Immunotherapy; Lymphoma; Myeloma

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DNA MODIFICATION; HODGKIN DISEASE; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; REVIEW; ANIMAL; AUTOGRAFT; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; PATHOLOGY; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; AUTOGRAFTS; HEMATOLOGIC NEOPLASMS; HUMANS; RECEPTORS, ANTIGEN, T-CELL; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84952639840     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.10.014     Document Type: Review

References (83)

1. Perales M.A., Ceberio I., Armand P., et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015, 21:971-983.
2. Shah N., Callander N., Ganguly S., et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015, 21:1155-1166.
3. Hahn T., Wolff S.N., Czuczman M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2001, 7:308-331.
4. Oliansky D.M., Czuczman M., Fisher R.I., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011, 17:20-47.e30.
5. Reddy N.M., Perales M.A. Stem cell transplantation in Hodgkin lymphoma. Hematol Oncol Clin North Am 2014, 28:1097-1112.
6. Giralt S., Garderet L., Durie B., et al. American Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 2015, 21:2039-2051.
7. Chen Y.B., Lane A.A., Logan B.R., et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015, 21:1046-1053.
8. Hourigan C.S., McCarthy P., de Lima M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:154-163.
9. Curran K.J., Brentjens R.J. Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol 2015, 33:1703-1706.
10. Davila M.L., Bouhassira D.C., Park J.H., et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2014, 99:361-371.
11. Kershaw M.H., Westwood J.A., Darcy P.K. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013, 13:525-541.
12. Ansell S.M. Targeting immune checkpoints in lymphoma. Curr Opin Hematol 2015, 22:337-342.
13. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015, 125:3393-3400.
14. Lendvai N., Cohen A.D., Cho H.J. Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant 2015, 50:770-780.
15. Davila M.L., Riviere I., Wang X., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014, 6:224ra225.
16. Brentjens R.J., Davila M.L., Riviere I., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5:177ra138.
17. Brentjens R.J., Riviere I., Park J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
18. Maude S.L., Frey N., Shaw P.A., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014, 371:1507-1517.
19. Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
20. Lee D.W., Kochenderfer J.N., Stetler-Stevenson M., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015, 385:517-528.
21. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993, 90:720-724.
22. Hombach A., Wieczarkowiecz A., Marquardt T., et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001, 167:6123-6131.
23. Brentjens R.J., Latouche J.B., Santos E., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003, 9:279-286.
24. Jensen M.C., Popplewell L., Cooper L.J., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010, 16:1245-1256.
25. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
26. Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015, 33:540-549.
27. Kochenderfer J.N., Somerville R., Lu L., et al. Anti-CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma. Blood 2014, 124:550.
28. Schuster S.J., Svoboda J., Nasta S., et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. J Clin Oncol 2015, 33(suppl):8516.
29. Turtle C.J., Berger C., Sommermeyer D., et al. Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition. J Clin Oncol 2015, 33(suppl):3006.
30. Sommermeyer D., Hudecek M., Kosasih P.L., et al. Chimeric antigen receptor-modified T cells derived from defined CD8 and CD4 subsets confer superior antitumor reactivity in vivo. Leukemia 2015, [Epub ahead of print]. 10.1038/leu.2015.247.
31. Sauter C.S., Riviere I., Bernal Y., et al. Phase I trial of 19-28z chimeric antigen modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). J Clin Oncol 2015, 33:8515.
32. Lee D.W., Gardner R., Porter D.L., et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014, 124:188-195.
33. Di Stasi A., Tey S.K., Dotti G., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, 365:1673-1683.
34. Pegram H.J., Lee J.C., Hayman E.G., et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012, 119:4133-4141.
35. Kloss C.C., Condomines M., Cartellieri M., et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013, 31:71-75.
36. Abate-Daga D., Hanada K., Davis J.L., et al. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood 2013, 122:1399-1410.
37. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015, 33:1974-1982.
38. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
39. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
40. Robert C., Ribas A., Wolchok J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
41. Topalian S.L., Sznol M., McDermott D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32:1020-1030.
42. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
43. Powles T., Eder J.P., Fine G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
44. Herbst R.S., Soria J.C., Kowanetz M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
45. Berger R., Rotem-Yehudar R., Slama G., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
46. Westin J.R., Chu F., Zhang M., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014, 15:69-77.
47. Ansell S.M., Hurvitz S.A., Koenig P.A., et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009, 15:6446-6453.
48. Moskowitz C.H., Ribrag V., Michot J.-M., et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood 2014, 124:290.
49. Ansell S.M., Lesokhin A.M., Borrello I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372:311-319.
50. Green M.R., Monti S., Rodig S.J., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116:3268-3277.
51. Chen B.J., Chapuy B., Ouyang J., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013, 19:3462-3473.
52. Armand P., Timmerman J.M., Lesokhin A.M., et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (ca209-039). Haematologica 2015, 100(s1):323.
53. Lesokhin A.M., Ansell S.M., Armand P., et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 2014, 124:291.
54. Guillaume T., Rubinstein D.B., Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998, 92:1471-1490.
55. Porrata L.F., Litzow M.R., Markovic S.N. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc 2001, 76:407-412.
56. Armand P., Nagler A., Weller E.A., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013, 31:4199-4206.
57. Armand P., Welch S., Kim H.T., et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol 2013, 160:608-617.
58. Sauter C.S., Matasar M.J., Meikle J., et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood 2015, 125:2579-2581.
59. Toffalori C., Riba M., Zito L., et al. Acute myeloid leukemia relapses after allogenenic HSCT display a distinctive immune-related signature, with frequent and functionally relevant alterations in HLA class II antigen presentation and T cell costimulation. Blood 2014, 124:427.
60. Bachireddy P., Hainz U., Rooney M., et al. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 2014, 123:1412-1421.
61. Bashey A., Medina B., Corringham S., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1581-1588.
62. Davids M.S., Kim H.T., Costello C.L., et al. Updated results of a multicenter phase I/Ib study of ctla4 blockade with ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Haematologica 2015, 100(s1):159.
63. Saha A., Aoyama K., Taylor P.A., et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 2013, 122:3062-3073.
64. Atanackovic D., Arfsten J., Cao Y., et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007, 109:1103-1112.
65. Goodyear O., Piper K., Khan N., et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 2005, 106:4217-4224.
66. van Rhee F., Szmania S.M., Zhan F., et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005, 105:3939-3944.
67. Tyler E.M., Jungbluth A.A., Gnjatic S., et al. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma. Cancer immunology research 2014, 2:547-558.
68. Tyler E.M., Jungbluth A.A., O'Reilly R.J., Koehne G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood 2013, 121:308-317.
69. Tyler E.M., Koehne G. The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect. Oncoimmunology 2013, 2:e24963.
70. Diab A., Jenq R.R., Rizzuto G.A., et al. Enhanced responses to tumor immunization following total body irradiation are time-dependent. PLoS One 2013, 8:e82496.
71. Rapoport A.P., Aqui N.A., Stadtmauer E.A., et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2011, 117:788-797.
72. Rapoport A.P., Stadtmauer E.A., Aqui N., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005, 11:1230-1237.
73. Perales M.A., Diab A., Cohen A.D., et al. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. J Immunol 2006, 177:4159-4167.
74. Garfall A.L., Maus M.V., Hwang W.T., et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 2015, 373:1040-1047.
75. Garfall A.L., Maus M.V., Lacey S.F., et al. Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. J Clin Oncol 2015, 33:8517.
76. Rapoport A.P., Stadtmauer E.A., Binder-Scholl G.K., et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015, 21:914-921.
77. Chu J., Deng Y., Benson D.M., et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014, 28:917-927.
78. Chu J., He S., Deng Y., et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res 2014, 20:3989-4000.
79. Garfall A.L., Fraietta J.A., Maus M.V. Immunotherapy with chimeric antigen receptors for multiple myeloma. Discov Med 2014, 17:37-46.
80. Atanackovic D., Luetkens T., Kroger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2014, 28:993-1000.
81. Ray A., Das D.S., Song Y., et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia 2015, 29:1441-1444.
82. Benson D.M., Bakan C.E., Mishra A., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010, 116:2286-2294.
83. Suen H., Brown R., Yang S., et al. The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study. Leukemia 2015, 29:1621-1622.